PET-CT of ovarian cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBUCHPIGUEL, C. A.
dc.date.accessioned2023-12-04T19:36:08Z
dc.date.available2023-12-04T19:36:08Z
dc.date.issued2011
dc.description.abstractPET-CT has no current role in the initial diagnosis of ovarian cancer. While imaging studies are not the basis of staging, imaging studies are often performed preoperatively (usually CT or MRI of the abdomen and pelvis) on patients suspected of advanced disease. A major advantage of PET-CT is the registered and aligned nature of the detailed anatomic images generated by the multidetector CT technology with the images of tissue metabolism possible by the PET technology. This allows for staging based on anatomic classification such as determining local extension of tumor into adjacent structures. Moreover, subtle metabolic abnormalities on FDG PET can be missed or misinterpreted as physiologic concentration of tracer, and the coregistration of the PET images with CT helps to further identify the lesion based on morphologic criteria. © 2011 Springer Science+Business Media, LLC.
dc.identifier.citationBuchpiguel, C. A.. PET-CT of ovarian cancer. In: . Clinical PET-CT in Radiology: Integrated Imaging in Oncology: SPRINGER NEW YORK, 2011. p.331-338.
dc.identifier.doi10.1007/978-0-387-48902-5_25
dc.identifier.isbn978-038748900-1
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57183
dc.language.isoeng
dc.publisherSPRINGER NEW YORK
dc.relation.ispartofClinical PET-CT in Radiology: Integrated Imaging in Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright SPRINGER NEW YORK
dc.titlePET-CT of ovarian cancer
dc.typebookPart
dc.type.categorybook chapter
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcCARLOS ALBERTO BUCHPIGUEL
hcfmusp.description.beginpage331
hcfmusp.description.endpage338
hcfmusp.origemScopus
hcfmusp.origem.scopus2-s2.0-84892865610
hcfmusp.relation.referenceJemal A., Thomas A., Murray T., Thun M., Cancer statistics, 2002, CA Cancer J Clin, 52, pp. 23-47, (2002)
hcfmusp.relation.referenceThe new FIGO stage grouping for primary carcinoma of the ovary (1985), Gynecol Oncol, 25, (1986)
hcfmusp.relation.referencePiver M.S., Baker T.R., Jishi M.F., Sandecki A.M., Tsukada Y., Natarajan N., Mettlin C.J., Blake C.A., Familial ovarian cancer: A report of 658 families from the gilda radner familial ovarian cancer registry (1981-1991), Cancer, 71, pp. 582-588, (1993)
hcfmusp.relation.referenceCasey M.J., Gupta N.C., Muths C.K., Experience with positron emission tomography (PET) scans in patients with ovarian cancer, Gynecol Oncol, 53, pp. 331-338, (1994)
hcfmusp.relation.referenceRieber A., Nussle K., Stohr I., Grab D., Fenchel S., Kreienberg R., Reske S.N., Brambs H.J., Preoperative diagnosis of ovarian tumors with MR imaging: Comparison with transvaginal sonography, positron emission tomography, and histologic findings, Am J Roentgenol, 177, pp. 123-129, (2001)
hcfmusp.relation.referenceLerman H., Metser U., Grisaru D., Fishman A., Lievshitz G., Even-Sapir E., Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: Assessment by PET/ CT, J Nucl Med, 45, pp. 266-271, (2004)
hcfmusp.relation.referenceFenchel S., Grab D., Nussle K., Kotzerke J., Rieber A., Kreienberg R., Brambs H.J., Reske S.N., Asymptomatic adnexal masses: Correlation of FDG PET and histopathologic findings, Radiology, 223, pp. 780-788, (2002)
hcfmusp.relation.referenceRisum S., Hogdall C., Loft A., Et al., The diagnostic value of PET/CT for primary ovarian cancer-a prospective study, Gynecol Oncol, 105, 1, pp. 145-149, (2007)
hcfmusp.relation.referenceCancer Society A., Cancer facts and figures: 1998, Atlanta: American Cancer Society, 13, (1998)
hcfmusp.relation.referenceKuhn W., Rutke S., Spathe K., Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma, Cancer, 92, pp. 2585-2591, (2001)
hcfmusp.relation.referenceTempany C.M.C., Zou K.H., Silverman S.G., Brown D.L., Kurtz A.B., McNeil B.J., Staging of advanced ovarian cancer: Comparison of imaging modalities, Radiology, 215, pp. 761-767, (2000)
hcfmusp.relation.referenceYoshida Y., Kurokawa T., Kawahara K., Tsuchida T., Okazawa H., Fujibayashi Y., Yonekura Y., Kotsuji F., Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer, Am J Roentgenol, 182, pp. 227-233, (2004)
hcfmusp.relation.referenceGadducci A., Cosio S., Surveillance of patients after initial treatment of ovarian cancer, Crit Rev Oncol Hematol, 71, 1, pp. 43-52, (2009)
hcfmusp.relation.referenceRubin S.C., Hoskins W.J., Hakes T.B., Markman M., Reichman B.S., Chapman D., Lewis Jr. J.L., Serum CA125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer, Am J Obstet Gynecol, 160, pp. 667-671, (1989)
hcfmusp.relation.referenceKim E.E., Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology, Int J Gynecol Cancer, 14, pp. 12-22, (2004)
hcfmusp.relation.referenceSironi S., Messa C., Mangili G., Et al., Integrated FDG PET/CT in patients with persistent ovarian cancer: Correlation with histologic findings, Radiology, 233, pp. 433-440, (2004)
hcfmusp.relation.referenceSebastian S., Lee S.I., Horowitz N.S., Et al., PET-CT vs. CT alone in ovarian cancer recurrence, Abdom Imaging, 33, pp. 112-118, (2008)
hcfmusp.relation.referencePoveda A., Ovarian cancer treatment: What is new?, Int J Gynecol Cancer, 13, pp. 241-250, (2003)
hcfmusp.relation.referenceSimcock B., Neesham D., Quinn M., Et al., The impact of PET/CT in the management of recurrent ovarian cancer, Gynecol Oncol, 103, 1, pp. 271-276, (2006)
hcfmusp.relation.referencePatsner B., Is there a role for CT scanning to monitor therapy of optimally debulked patients with advanced ovarian epithelial cancer?, Int J Gynecol Cancer, 4, pp. 19-21, (1994)
hcfmusp.relation.referenceAvril N., Sassen S., Schmalfeldt B., Et al., Prediction of response to neoadjuvant chemotherapy by sequential F-18 fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer, J Clin Oncol, 23, pp. 7445-7453, (2005)
hcfmusp.relation.referenceRisum S., Hogdall C., Loft A., Et al., Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-a prospective study, Gynecol Oncol, 108, 2, pp. 265-270, (2008)
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication6fcbbc21-1ba0-4023-a2cd-0e709b22f5c3
relation.isAuthorOfPublication.latestForDiscovery6fcbbc21-1ba0-4023-a2cd-0e709b22f5c3
Arquivos
Coleções
Livros e Capítulos de Livros - FM/MDR
Livros e Capítulos de Livros - HC/ICHC
Livros e Capítulos de Livros - LIM/43